Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Reducing the severity of respiratory disease
The effect of immune-modulators in equine medicine

An Animal Health Trust (AHT) review has found that immune-modulators can reduce the severity of some respiratory diseases in horses.

The review, which has been published in Veterinary Immunology and Immunopathology, was conducted by Romain Paillot, who works at AHT.

His work involved examining scientific literature and reports on the use of immune-modulators in equine medicine, in particular, for the prevention or treatment of respiratory disease.

The two immune-modulators studied were Parapoxvirus ovis (iPPVO) and Propionbacterium acnes (P.acnes), which are both used to improve immune defences and prevent or treat infectious diseases in horses.

Dr Paillot found that young horses treated with iPPVO and co-mingled with experimentally infected EHV-1 horses showed a reduction in disease severity by 40 per cent.

Meanwhile, those treated with iPPVO and co-mingled with horses experimentally infected with EHV-4 showed a 61 per cent reduction in disease severity.

For horses treated with P.acnes, Dr Paillot found that the frequency of recovery for horses that had shown clinical signs of respiratory disease were "significantly increased".

He said: "Non-specific immune-modulators such as iPPVO or P.acnes may not provide protection against direct infection or transmission of respiratory pathogens, but they seem to contribute to the reduction of the disease severity.

"This subsequently reduces the frequency of complications and improves the rate of recovery."

Click here to read the review.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.